Cory Ruddy-Ramirez
Family Medicine · Bronx, NYNPI 1538422944
Payments from drug & device makers
Across 92 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$587
- Novo Nordisk$329
- Lilly USA, LLC$222
- Astellas Pharma US Inc$156
- Shield Therapeutics Inc$128
- Exact Sciences$120
- plus $526 from 12 others
What the payments were for
- Food & beverage$2,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 27 | $587 |
| Novo Nordisk | 16 | $329 |
| Lilly USA, LLC | 9 | $222 |
| Astellas Pharma US Inc | 5 | $156 |
| Shield Therapeutics Inc | 6 | $128 |
| Exact Sciences | 5 | $120 |
| AbbVie | 4 | $118 |
| Merck | 5 | $98 |
| Pfizer | 3 | $68 |
| AstraZeneca | 3 | $56 |
| Novartis | 2 | $39 |
| Dynavax Technologies Corporation | 1 | $33 |
| Grifols USA, LLC | 1 | $24 |
| Amgen | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $14 |
How this compares
$2,068 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 171 | $169,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 225 | $145,879 |
| TrulicityDulaglutide | 89 | $91,935 |
| FarxigaDapagliflozin Propanediol | 45 | $44,715 |
| JanuviaSitagliptin Phosphate | 50 | $39,310 |
| JardianceEmpagliflozin | 30 | $38,029 |
| UbrelvyUbrogepant | 34 | $33,976 |
| VascepaIcosapent Ethyl | 34 | $21,932 |
| Diclofenac Sodium | 111 | $19,627 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $18,679 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $18,027 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 89 | $17,616 |
| XareltoRivaroxaban | 28 | $17,211 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 565 | $16,639 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $16,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $329 | $169,901171 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $587 | $167,454273 claims |
| Lilly USA, LLCTrulicity | $222 | $91,93589 claims |
| AbbVieUbrelvy, Creon, Linzess | $118 | $55,90962 claims |
| AstraZenecaFarxiga, Symbicort | $56 | $52,68983 claims |
| MerckJanuvia | $98 | $39,31050 claims |
| PfizerEliquis | $68 | $12,00916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.
Other family medicine in Bronx
- Eugene SchiffBronx$184K
- Hui-Li HuangBronx$41K
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.